双氯芬酸钠(Diclofenac Sodium) - 药物靶点：COXs_在研适应症：滑囊炎，颈臂综合征，腰痛_专利_临床

概要

基本信息

简介双氯酚酸钠是苯乙酸衍生物，是一种非甾体抗炎药（NSAID），具有镇痛、抗炎和解热作用。和其他NSAIDs一样，双氯酚酸钠的作用机制尚未完全理解，但涉及抑制环氧化酶（COX-1和COX-2）。FDA于1988年7月28日批准双氯酚酸钠（VOLTAREN ）上市，其原产公司为Ciba-Geigy公司，现已并入诺华。这种药物已经长期用于管理多种疼痛症状，并且有处方和非处方制剂

药物类型

小分子化药

别名

Diclfenac Sodium、Diclofanac Sodium、DICLOFENAC

+ [119]

靶点

COXs

作用方式

抑制剂

作用机制

COX抑制剂(环氧化酶抑制剂)

治疗领域

免疫系统疾病神经系统疾病皮肤和肌肉骨骼疾病+ [5]

在研适应症

滑囊炎颈臂综合征腰痛+ [22]

非在研适应症

光化性角化病晚期恶性实体瘤踝损伤+ [12]

原研机构

Novartis Pharma AG

在研机构

Amzell Ltd.

Dojin Iyaku-Kako Co., Ltd.

Hisamitsu Pharmaceutical Co., Inc.

+ [10]

非在研机构

Novartis Pharmaceuticals Corp.

Novartis AGJAVELIN PHARMACEUTICALS INC A WHOLLY OWNED SUDSIDIARY OF HOSPIRA INC

+ [7]

权益机构

Dr. Reddy's Laboratories Ltd.

Mundipharma International Ltd.

Sayre Therapeutics Pvt Ltd.

+ [9]

最高研发阶段批准上市

首次获批日期

日本 (1973-08-08),

炎症疼痛

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C14H11Cl2NNaO2

InChIKeyVSFBPYWDRANDLM-UHFFFAOYSA-N

CAS号15307-79-6

关联

616

项与双氯芬酸钠相关的临床试验

NCT06207253

/ Recruiting临床2/3期IIT

The Antimicrobial Potential of Diclofenac Sodium as an Intracanal Medicament During Root Canal Treatment: A Randomized Clinical Trial

The goal of this randomized clinical trial is to evaluate the capability of the material to exert bacterial reduction of diclofenac sodium versus of that calcium hydroxide paste when these materials are used as intracanal medications in permanent molar teeth with chronic apical periodontitis.
The main question[s] it aims to answer are:
• Will the diclofenac sodium (NSAIDs) possess antimicrobial efficacy to be used effectively as an intracanal medicament similar to that of calcium hydroxide in primary endodontic treatment? Participants will be allocated randomly into three equal groups by using computer generated randomization, according to the type of intracanal medication.

开始日期2025-11-01

申办/合作机构

British University of Egypt

NCT07079969

/ Not yet recruiting临床2期IIT

Effects of Photobiomodulation and Topical Diclofenac on Inflammation and Pain in Knee Osteoarthritis

This study aims to compare the effects of combined treatments-dual-wavelength photobiomodulation (PBM) with or without topical diclofenac-on inflammation, pain, and joint function in patients with knee osteoarthritis (OA). It also seeks to determine the synergistic effect of PBM plus topical diclofenac on inflammatory markers, pain scores, and functional outcomes.

开始日期2025-08-01

申办/合作机构

University of Florida

CTRI/2025/04/085521

/ Not yet recruiting临床2期IIT

Evaluation of Gandhaka Rasayana Rectal Suppository and Diclofenac Sodium Suppository in Post Operative Pain Management in Fissure-in-Ano: A Single Blind Non-randomized controlled clinical trial - NIL

开始日期2025-07-01

申办/合作机构-

100 项与双氯芬酸钠相关的临床结果

登录后查看更多信息

100 项与双氯芬酸钠相关的转化医学

登录后查看更多信息

100 项与双氯芬酸钠相关的专利（医药）

登录后查看更多信息

24,546

项与双氯芬酸钠相关的文献（医药）

2025-12-01·Water Research X

Micropollutants removal, residual risk, and costs for quaternary treatments in the framework of the Urban Wastewater Treatment Directive

作者: Antonelli, Manuela ; Piraldi, Sara ; Ianes, Jessica ; Cantoni, Beatrice

The revised Urban Wastewater Treatment Directive (UWWTD) imposes stringent regulations for the removal of micropollutants from urban wastewater treatment plants.The analyses conducted in this study are based on current knowledge extrapolated from literature WWTPs, to investigate the occurrence, removal and environmental risk related to the 12 target micropollutants: Amisulpride, Benzotriazole, 4,5-Methylbenzotriazole, Carbamazepine, Clarithromycin, Citalopram, Candesartan, Diclofenac, Hydrochlorothiazide, Irbesartan, Metoprolol, and Venlafaxine.The goal is to provide valuable insights into the challenges and opportunities associated with implementing quaternary treatment processes to comply with the UWWTD.It indicate that the conventional biol. treatment is insufficient, with median removal rates below 50% for most target micropollutants (except for Benzotriazole and Irbesartan).The implementation of quaternary treatment processes, namely ozonation and activated carbon adsorption, significantly enhances WWTP micropollutants removal, with median removal efficiencies exceeding 80% for all the target micropollutants, with Candesartan being the most recalcitrant.Environmental risk assessment reveals that some micropollutants pose a significant threat to aquatic ecosystems even with 80% removal efficiency (Irbesartan, Candesartan, Diclofenac, and Venlafaxine), while others do not pose a risk even at WWTP influent concentrations (4,5-Methylbenzotriazole, Hydrochlorothiazide, Amisulpride, Citalopram, and Metoprolol).Economic anal. shows that the selection of specific operating parameter values significantly impacts the cost of each treatment process, changing the economic feasibility ranking of the different treatment options.

2025-11-01·APPLIED CATALYSIS B-ENVIRONMENTAL

Identification of reactive species and functional groups determining the selective oxidation of organic contaminants in Bismuth ferrate/peroxymonosulfate system

作者: Shao, Dan ; Zhang, Yuanyuan ; Rao, Yongfang ; Yan, Wei ; Cui, Jiahao ; Cui, Miaoying

The reactive species and functional groups determining the major reactive species contributing to the degradation of organic pollutants were identified in the Bi₂Fe₄O₉/PMS (BFO/PMS) system.Competitive degradation, radical quenching experiments of organic contaminants, PMSO₂ generation, Raman spectroscopy, ¹⁸O isotope labeling experiments and the comparison of sulfadiazine degradation intermediates suggest the generation of both free radical and high-valent iron in BFO/PMS system.The groups determining the high-valent iron oxidation pathways for different organic contaminants were identified resp. (acetaminophen: -OH, sulfadiazine: -NH₂, diclofenac: -NH-, ciprofloxacin: -NH- and N-R3).The linear relationship between Hammett′s constants and the contribution of high-valent iron oxidation to the degradation of homologues under neutral condition was established.This study provides a novel insight into heterogeneous activation mechanisms of PMS and helps predict the fate of various organic pollutants carrying different functional groups during environmental remediation by the activation of PMS by iron-based catalysts.

2025-11-01·JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY

Effect of microplastics on the photodegradation of high-consumption drugs under simulated sunlight: The critical role of aging and reactive oxygen species

作者: Kalaronis, Dimitrios ; Kyzas, George Z. ; Bikiaris, Dimitrios N. ; Evgenidou, Eleni ; Lambropoulou, Dimitra A. ; Teknetzi, Aikaterini ; Vourlias, George

The main aim of this study was to examine the effect of polypropylene (PP), poly(ethylene terephthalate) (PET), and poly(lactic acid) (PLA) microplastics (MPs) on the photolytic degradation of a mixture of seven commonly used pharmaceuticals under simulated solar irradiation (SSL).The target mixture included four common antibiotics (metronidazole, trimethoprim, indomethacin, isoniazid), two non-steroidal anti-inflammatory drugs (diclofenac, ketoprofen), and one antihypertensive drug (valsartan).The selected MPs were aged using three different procedures: (i) SSL light, (ii) UV/H₂O₂, and (iii) Fenton reagent.The effect of MPs mass concentration was examined using only the pristine MPs, while the aging effect was evaluated for the three different aged MPs for each polymer type.The results demonstrated that the presence of MPs generally accelerates the photolytic degradation of the drugs, and increasing their concentration further enhances the reaction rate.Aging of the MPs also appeared to enhance the photodegradation of the selected pharmaceuticals.Among the various aging processes applied, UV/H2O2 had the greatest impact on surface alteration of the MPs and consequently, UV/H₂O₂-aged PET MPs exhibited the highest influence on the photolytic degradation of the drugs.To gain a deeper understanding of the mechanism behind the photolytic degradation of the examined pharmaceuticals, a systematic characterization of pristine and aged MPs was conducted using Fourier transformed IR spectroscopy (FTIR), XPS, and SEM-energy dispersive X-ray spectroscopy (SEM-EDX) techniques, which detected the formation of oxygen containing groups on the MPs' surfaces.Finally, scavenger experiments were also conducted to explore the formation and role of reactive oxygen species (singlet oxygen, superoxide anions, and hydroxyl radicals) in the degradation of the target compounds

212

项与双氯芬酸钠相关的新闻（医药）

2025-07-21

·EINPresswire

HimGo may be harmful due to hidden drug ingredients

[2-10-2025] The Food and Drug Administration is advising consumers not to purchase or use HimGo, a product promoted and sold for sexual enhancement on various websites, including ebay.com, and possibly in some retail stores. FDA laboratory analysis confirmed that HimGo contains sildenafil and diclofenac not listed on the product label. Sildenafil is the active ingredient in the FDA-approved prescription drug Viagra, used to treat erectile dysfunction. FDA approval of Viagra is restricted to use under the supervision of a licensed health care professional. This undeclared ingredient may interact with nitrates found in some prescription drugs, such as nitroglycerin, and may lower blood pressure to dangerous levels. People with diabetes, high blood pressure, high cholesterol, or heart disease often take nitrates. Diclofenac is a non-steroidal anti-inflammatory drug (NSAID). NSAIDs may cause increased risk of cardiovascular events, such as heart attack and stroke, as well as serious gastrointestinal damage, including bleeding, ulceration, and fatal perforation of the stomach and intestines. This hidden drug ingredient may also interact with other medications and significantly increase the risk of adverse events, particularly when consumers use multiple NSAID-containing products. Health care professionals and consumers should report adverse events or side effects related to the use of this product to FDA's MedWatch Safety Information and Adverse Event Reporting Program: Note: This notification is to inform the public of products potentially marketed as dietary supplements or conventional foods with hidden drug ingredients and chemicals. These products are typically promoted for sexual enhancement, weight loss, pain relief and body building and are often represented as being "all natural." FDA is unable to test and identify all products marketed as dietary supplements that have potentially harmful hidden ingredients. Consumers should exercise caution before purchasing any product in the above categories. Refer to the links below for more information: Content current as of: 07/21/2025 Regulated Product(s) Topic(s) Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

2025-07-13

·金诃藏药

「藏医论痛风」藏医外治法速效干预痛风密码

藏医外治作为非物质文化遗产，具有深厚的文化价值。它不仅是藏医学的重要组成部分，更是中华文化的瑰宝。藏医外治融合了自然观、人文观和医学观，体现了中华民族对健康的独特理解和追求，其独特的理论体系和疗效，在当今社会仍然具有重要的意义和应用价值。放血疗法痛风性关节炎多为热证，藏医常使用放血疗法刺于发病部位或近患处的静脉进行放血，主要适用于“赤巴型”直合乃，放血前一般会服用“三果汤”分离正常血液和“坏血”，使病邪随“坏血”流出，以达到迅速缓解症状的目的。放血疗法多遵循“少放多次”原则，常配以内服汤药以增疗效[1-2]。放血疗法在临床病例中有大量报道，青海省藏医院随机抽取20例痛风患者开展藏医放血治疗，痊愈率逾 65%[2]。多项临床研究表明放血疗法与相关炎症因子变化密切相关，经放血治疗后，局部与全身的炎症因子 IL-1β、TNF-α、HIF-1α 以及炎症小体 NLRP3 含量下降，此外，放血疗法还可影响血尿酸水平[3-5]，提示此疗法可能通过减少细胞炎症因子产生、降低体内尿酸水平等多种途径缓解病证。药浴藏医药浴是药物经过皮肤透皮吸收的治疗方法，藏语称为“泷沐”，藏医认为沐浴温度能够打开腠理并加速药物的吸收，活性物质的作用也能加速局部血液循环促进病灶代谢。同时，药浴还会通过发汗加速邪气的排出[6]。五味甘露药浴常被用于治疗多种关节炎疾病，通过药浴可以使患处发汗以加速黄水排出，治疗关节湿邪所致的弊病、肿痛。梁宏达等[7]将72例急性痛风关节炎患者随机分为两组，其中一组在口服双氯芬酸钠治疗7d(75mg/ 次，1次/d)的同时使用五味甘露药浴1次，相较于单用西药治疗组，药浴组的临床疗效更优，其疼痛评分更低。同时，在耳肿胀模型、醋酸扭体试验等动物实验中，五味甘露药浴贴表现出了较好的抗炎镇痛作用[8]。外敷藏医外敷是藏医药理论体系下的常用治疗项目，一般是在内服药物的同时，加以外用药敷用，以达到消肿化瘀、活血通经的目的。此种方法简单快捷、成本低廉，主要适用于“赤巴型”直合乃。青海省藏医院所报道的32例痛风性关节炎患者收治入院后外敷使用了院内制剂痛风消痛涂剂(3次/d，连续1w)，加服秋水仙碱(按说明书服用，疼痛消退后 0.5mg/d)，有效率为96.8%，高于单用秋水仙碱组(有效率为88.8%)，关节疼痛肿胀以及血尿酸水平均明显更低[9]。火炙藏医火灸是藏医经典外治法之一，火灸常用针刺法，多针对于“隆型”直合乃，最早可追溯至公元前 100年。灸法是通过穴位能够传导刺激信号到达病变部位，对失调的病灶及其代谢紊乱进行调节以达到治疗目的[10]。刺血疗法与艾灸联用治疗痛风性关节炎疗效尚佳。有研究报道，在MSU诱导的大鼠急性痛风性关节炎模型中，治疗组采用艾灸联用刺血疗法(1次/d)，连续3d。结果显示，相较于模型组，接受刺血疗法的大鼠足肿胀度显著下降，并且相较于秋水仙碱0.135 mg/kg组，连续灌胃3d，也具有显著差异[11]。现代医学研究发现，艾灸能够通过温热刺激免疫系统进行机体调节进而达到机体自行清除病灶、改善关节活动能力的目的[12]。藏医药抗痛风的特色疗法总结见下图。藏医治疗痛风的外治疗法具有综合调理的优势，副作用少，能够从根本上调理身体，灵活应对患者的病情变化。此外，藏医注重整体调理，强调身心平衡，不仅治疗痛风症状，还能改善患者的整体健康状况。原文献：[1]李敏1,2,郎吉瑞1,李延芳3,陈蓉4,李莉1,全云云1,王婷1,刘丽1,曾瑾1,尹竹君1∗∗,赵军宁1,2∗∗. 痛风和高尿酸血症的藏医药治疗研究进展[J].中药药理与临床,2024,40(11):120-128.研究单位：1.四川省中医药科学院,四川省中医药转化医学中心,国家中医药管理局中药质量生物评价重点研究室,中医药转化医学四川省重点实验室,四川省道地药材形成原理与品质评价工程研究中心,四川省道地药材系统开发工程技术研究中心;2.成都中医药大学药学院;3.四川大学化学工程学院;4.成都中医药大学民族医药学院。参考文献：[1]卢旭亚,克珠,郎加,等. 藏医放血疗法治疗痛风研究进展[ J]. 中华中医药杂志,2019,34(8):3647-3649.[2]仁青措. 藏医放血疗法治疗赤巴型头痛病的临床疗效[ J]. 中国民族医药杂志,2021,27(4):39-40.[3]董伯岩,克珠,卢旭亚. 藏医放血疗法对急性痛风局部 NLRP3、S100A8 / A9 和 IL-1β 的影响[J]. 西部中医药,2020,33(10):87-89.[4]卢旭亚,克珠,贺国波. 藏医放血疗法对急性痛风全身及局部 NLRP3、IL-4 和 CXCL2 的影响[J]. 中国中医基础医学杂志,2020,26(3):354-356.[5]董伯岩,克珠,卢旭亚. 藏医放血疗法对急性痛风局部及全身炎性因子的影响[J]. 世界中医药,2020,15(3):446-449.[6]王汝珊,王洪玲,罗婕,等. 藏药五味甘露药浴方的临床应用规范化研究[J]. 中药与临床,2021,12(2):59-64.[7]梁宏达,王吉波,潘琳,等. 五味甘露药浴颗粒治疗急性痛风关节炎的临床观察[J]. 中华全科医学,2011,9(12):1863-1865.[8]王红,严倩云. 高原抗风湿藏药五味甘露药浴帖抗炎镇痛药理学研究[J]. 高原医学杂志,2017,27(1):23-25.[9]杨本扎西. 藏药痛风消痛涂剂治疗急性痛风性关节炎 32 例临床观察[J]. 中国民族民间医药,2014,23(22):3-10.[10]南知周本. 藏医火灸疗法简述[ J]. 中国民族医药杂志,2014,20(8):15.[11]朱艳. 刺血加艾灸疗法对急性痛风性关节炎大鼠外周血单个核细胞TLR2与TLR4 mRNA 表达的影响[J]. 安徽中医药大学学报,2014,33(1):47-50.[12]赵文亮,江勉君,秦敏. 刺血疗法多样联合治疗痛风性关节炎的理论初探[J]. 中医药学报,2020,48(11):56-59.部分内容由AI生成，图片来源于网络，版权属于原作者，如有侵权，请联系删除。编辑：边圣杰；审核：陈文文；总编：牛豫娟

临床研究放射疗法

2025-07-13

·药闻康策

中国这家合资药企，正式告别历史舞台

☝ 点击上方一键预约 ☝ 最新最热的医药健康新闻政策赫力昂中国近日宣布，已完成对中美史克中方股东的全部股权收购，实现对该公司的全资控股。自此，这家承载着中国医药行业特殊记忆的合资企业，彻底告别历史舞台。中美天津史克制药有限公司（简称“中美史克”）正式终结近40年合资历史！再见了，“中美史克”！“中美史克”四个字，承载了太多时代印记。作为改革开放后中国首批合资制药企业，中美史克成立于1984年，其合资方为天津中新药业集团股份有限公司、天津市医药集团及葛兰素史克公司（GSK）。这一合作模式曾开创了中国医药行业先河。近40年来，中美史克为中国市场带来了诸多家喻户晓的药品品牌：- 芬必得（布洛芬缓释胶囊）——无数中国家庭的止痛常备药- 必理通（对乙酰氨基酚片）——经典退烧镇痛药- 新康泰克——广为人知的感冒药品牌- 百多邦（莫匹罗星软膏）——皮肤抗感染外用药这些品牌陪伴了几代中国消费者的健康生活，成为国民记忆中难以磨灭的一部分。“赫力昂”时代开启，全资控股布局中国此次股权变更并非突然之举。2022年7月，原隶属于葛兰素史克（GSK）的消费者保健业务部门正式分拆独立，以新公司赫力昂（Haleon）的身份登陆伦敦证券交易所，成为全球最大的独立消费者健康业务公司。赫力昂旗下汇聚了众多全球知名品牌，如舒适达（牙膏）、芬必得、扶他林（外用止痛）、钙尔奇（钙补充剂）、善存（维生素）以及本次收购对象——中美史克的核心品牌。此次完成对中方股东所持全部股权的收购，意味着赫力昂实现了对原中美史克的100%全资控股。一个时代的终结，一种模式的转变中美史克作为首批中外合资制药企业的历史正式落幕，标志着中国医药行业一个特定发展阶段的结束。其背后是中国医药市场环境的巨变：- 政策法规持续完善- 市场竞争日益激烈- 本土药企快速崛起- 跨国企业战略调整从“市场换技术”的合资探索，到跨国巨头追求更大自主权的独资运营，反映的是中国在全球医药健康产业中地位的提升，以及跨国企业在华发展策略的日益成熟和精细化。你家的药箱里，还有中美史克的老产品吗？（来源：蒲公英Ouryao)药闻康策新媒体矩阵微信公众号点击下方一键关注【免责声明】1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。欢迎转发分享、点赞、点在看

并购

100 项与双氯芬酸钠相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00904	双氯芬酸钠	M02AA15 D11AX18 M01AB05	DB00586

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
滑囊炎	日本	Hisamitsu Pharmaceutical Co., Inc.	2022-06-20
颈臂综合征	日本	Hisamitsu Pharmaceutical Co., Inc.	2022-06-20
腰痛	日本	Hisamitsu Pharmaceutical Co., Inc.	2022-06-20
癌症疼痛	日本	Hisamitsu Pharmaceutical Co., Inc.	2021-03-23
膝关节炎	美国	Horizon Therapeutics Ireland DAC	2014-01-16
骨关节炎	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
肩周炎	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
肌腱病	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
腱鞘炎	日本	Dojin Iyaku-Kako Co., Ltd.	2004-02-27
光化性角化病	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
超敏反应	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
怀孕	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
可见病灶	美国	Fougera Pharmaceuticals, Inc.	2000-10-16
术后炎症	日本	Wakamoto Pharmaceutical Co., Ltd.	1989-03-31
强直性脊柱炎	美国	Novartis Pharmaceuticals Corp.	1988-07-28
类风湿关节炎	美国	Novartis Pharmaceuticals Corp.	1988-07-28
炎症	日本	Fujisawa Pharmaceutical Co., Ltd.	1973-08-08
疼痛	日本	Fujisawa Pharmaceutical Co., Ltd.	1973-08-08

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肌痛	临床3期	美国	Novartis AG	2014-10-01
挫伤	临床3期	德国	Novartis AG	2011-01-01
四肢损伤	临床3期	德国	Novartis AG	2011-01-01
软组织损伤	临床3期	德国	Novartis AG	2011-01-01
踝损伤	临床3期	美国	Novartis AG	2010-11-01
晒伤	临床3期	法国	Novartis AG	2006-11-01
膝关节原发性骨关节炎 NOS	临床3期	美国	Nuvo Pharmaceuticals, Inc.	2004-02-01
痛风性关节炎	临床1期	中国	四川天德制药有限公司	2022-10-14
发热	临床1期	中国	四川天德制药有限公司	2022-10-14
头痛	临床1期	中国	四川天德制药有限公司	2022-10-14

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05947461 (DIPPP, Pubmed \| Gut)	N/A	ERCP术后胰腺炎	1,204	Rectal Diclofenac 100 mg	夢構憲鹽襯繭鹽鏇鹹襯(齋構糧網遞齋衊觸鹹廠) = 夢繭獵膚夢壓夢積獵製獵憲餘遞餘廠憲鏇糧憲 (選蓋築鏇鬱憲簾夢鹹膚 )	不佳	2025-07-01
				Rectal Indomethacin 100 mg	夢構憲鹽襯繭鹽鏇鹹襯(齋構糧網遞齋衊觸鹹廠) = 鹽衊鑰鬱蓋廠衊範餘淵獵憲餘遞餘廠憲鏇糧憲 (選蓋築鏇鬱憲簾夢鹹膚 )
NCT05968482 (CTgov)	临床1期	-	74	Diclofenac Sodium Gel (AMZ001 Low Dose)	醖鏇壓窪鬱淵壓齋糧獵(餘膚獵鏇艱膚鹽簾蓋廠) = 鏇醖淵簾廠繭鹽襯築簾範窪鑰壓鹹選糧淵簾艱 (窪淵憲淵繭憲衊獵膚壓, 89.8) 更多	-	2025-04-09
				Diclofenac Sodium Gel (AMZ001 High Dose)	醖鏇壓窪鬱淵壓齋糧獵(餘膚獵鏇艱膚鹽簾蓋廠) = 鏇願觸衊膚願築憲積餘範窪鑰壓鹹選糧淵簾艱 (窪淵憲淵繭憲衊獵膚壓, 90.3) 更多
ASCO2024	N/A	癌症疼痛	437	Diclofenac sodium suppository	艱蓋蓋積醖積構鬱選鏇(襯襯艱鹽選顧鑰艱範壓) = 5 pts experienced any grade treatment emergent adverse events (TEAEs). All TEAEs were grade 1-2. TEAE leading to treatment discontinuation was occurred in one pt. 蓋壓廠齋憲簾顧鑰選襯 (網鹹鹹壓鹽蓋醖獵積願 )	积极	2024-05-24
				Placebo
DDW2024	N/A	ERCP术后胰腺炎	-	Rectal diclofenac 100 mg	獵鹹網鑰繭鏇遞網網襯(鏇衊選鏇選範願構繭選) = Post ERCP pancreatitis (PEP) was observed in 3.2% (n=97) cases. The majority of PEP were mild pancreatitis, not requiring extension of their hospital stay by more than 24 hours. 12.37% of PEP cases were severe (n=12), with two mortality. 觸構憲糧襯獵鹹網齋夢 (襯淵製願壓製餘築簾鑰 )	-	2024-05-21
D-ToRCH (ESMO2023)	临床3期	-	264	Topical diclofenac	顧觸選製蓋齋鑰齋衊醖(廠顧鹽蓋夢鏇鏇壓鏇鏇) = 艱廠醖衊顧齋餘顧淵襯齋製窪鬱鏇繭鬱願鏇夢 (觸簾鬱齋窪簾鹽膚壓鹹 ) 更多	-	2023-10-21
				Placebo	顧觸選製蓋齋鑰齋衊醖(廠顧鹽蓋夢鏇鏇壓鏇鏇) = 淵願構艱鹹網繭窪夢壓齋製窪鬱鏇繭鬱願鏇夢 (觸簾鬱齋窪簾鹽膚壓鹹 ) 更多
NCT05829707 (NCT05829707, Pubmed)	临床4期	乳腺癌	120	Levobupivacaine wound infiltration	願醖膚夢廠鹹顧觸憲衊(觸鹽遞選齋憲範襯淵製) = 願製艱窪淵鏇膚願鏇夢衊選憲膚壓糧襯遞獵觸 (積網構廠顧襯願製範繭 ) 更多	积极	2023-08-23
				Diclofenac analgesia	願醖膚夢廠鹹顧觸憲衊(觸鹽遞選齋憲範襯淵製) = 艱網鏇膚齋廠艱廠鹹鑰衊選憲膚壓糧襯遞獵觸 (積網構廠顧襯願製範繭 ) 更多
NCT04683627 (Corporate Publications) 人工标引	临床3期	膝关节炎	370	HP-5000	獵鑰夢遞鬱淵憲淵襯壓(糧選鏇壓範齋襯顧鬱願) = The study did not meet its primary endpoint of statistically significant improvement in the osteoarthritis knee pain score (WOMAC) from baseline to week 12 繭遞選窪獵襯廠夢遞鏇 (夢糧衊鹹淵築網顧憲蓋 )	不佳	2022-10-28
				placebo
ESC2022	N/A	-	-	Initiators of diclofenac	衊鑰糧襯餘選鏇網選壓(餘鹹餘選鬱憲繭製鹽齋): IRR = 1.7 (95% CI, 1.55 ~ 1.86)	-	2022-08-27
				Non-initiators of diclofenac
EULAR2022	N/A	非放射性轴性脊柱关节炎	43	Continuous NSAIDs intake	窪鹽醖艱廠構膚選夢夢(襯憲鹽遞鑰築鹽範窪齋) = 廠繭鏇網夢艱壓餘製鹹醖餘餘構網遞鑰鏇齋簾 (齋鏇膚鬱糧簾顧餘廠鹹 ) 更多	积极	2022-06-01
				Occasional NSAIDs intake	襯蓋積醖襯鏇餘簾膚糧(選獵構鏇遞顧齋範夢膚) = 繭鏇築鬱憲糧選鬱齋壓觸鏇鬱憲繭蓋鹽鬱醖蓋 (遞襯製糧網醖製顧範鏇 )
NCT03861611 (CTgov)	临床4期	急性腰痛	198	Educational Intervention+Ketorolac (Ketorolac + Educational Intervention)	繭蓋夢鹽網蓋觸願窪簾(夢憲鬱鹹顧廠淵餘鑰糧) = 憲憲衊襯鏇艱鏇構艱齋醖餘壓繭鏇鹹糧鹹構繭 (簾顧淵醖獵鹽廠構範鑰, 8.8) 更多	-	2022-05-31
				Educational Intervention+Ibuprofen (Ibuprofen + Educational Intervention)	繭蓋夢鹽網蓋觸願窪簾(夢憲鬱鹹顧廠淵餘鑰糧) = 膚艱鏇壓築憲膚齋窪膚醖餘壓繭鏇鹹糧鹹構繭 (簾顧淵醖獵鹽廠構範鑰, 9.5) 更多